Show simple item record

dc.contributor.authorLópez‐Siguero, Juan P.
dc.contributor.authorMartínez‐Aedo, Maria J.
dc.contributor.authorBermúdez de la Vega, José Antonio
dc.contributor.authorBosch‐Muñoz, Jordi
dc.contributor.authorLechuga Sancho, Alfonso María 
dc.contributor.authorVillalobos, Triana
dc.contributor.authorSGA Study Investigator Collaborative Group
dc.contributor.otherMaterno-Infantil y Radiologíaes_ES
dc.date.accessioned2022-02-15T08:16:11Z
dc.date.available2022-02-15T08:16:11Z
dc.date.issued2021-12
dc.identifier.issn0300-0664
dc.identifier.issn1365-2265 (internet)
dc.identifier.urihttp://hdl.handle.net/10498/26261
dc.description.abstractObjective In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance (IR) has only been investigated for a short period, necessitating a longer observation period. This study aimed to evaluate the long-term (10 years) effect of GH to SGA-children on IR and safety during treatment. Design This was a multicenter observational study. Patients: SGA-children who received GH treatment in Spain (stratified by Tanner-stage and age at GH onset [two groups: <= 6 years old or >6 years old]). Measurements: The analysed variables (yearly measures) included auxologic, metabolic (insulin-like growth factor-1 (IGF-1), height velocity [HV], weight and homeostatic model assessment-IR [HOMA-IR]) and safety data. Data were collected prospectively (since the study approval: 2007) and retrospectively (since the initiation of GH treatment: 2005-2007). Results A total of 389 SGA children (369 Tanner-I) were recruited from 27 centres. The mean age (standard deviation) of the children at GH treatment onset was 7.2 (2.8) years old. IGF-1 (standard deviation score [SDS]) and HOMA-IR values tended to increase until the sixth year of GH-treatment, with significant differences being observed only during the first year, while these remained stable in the later years (within normal ranges). Height (SDS) increased significantly (basal: -3.0; tenth year: -1.13), and the maximum HV (SDS) occurred during the first year (2.75 +/- 2.39). Conclusions HOMA-IR values increased significantly in SGA-children during the first year of GH-treatment, remained stable and were within normal ranges in all cases. Our 10-year data suggests that long-term GH treatment does not promote IR and is well-tolerated, safe and effecties_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherWILEYes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceClinical Endocrinology. 2021;1–11es_ES
dc.subjectefficacyes_ES
dc.subjectgrowth hormonees_ES
dc.subjecthomeostatic model assessmentes_ES
dc.subjectinsulin resistancees_ES
dc.subjectlong‐term follow‐upes_ES
dc.subjectsafetyes_ES
dc.subjectsmall for gestational agees_ES
dc.titleGrowth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational studyes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1111/cen.14626


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional